Outlook Therapeutics, Inc.
OTLK
$0.39
$0.0410.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -62.07% | -44.94% | -32.38% | -- | 113.28% |
| Gross Profit | 49.57% | 44.21% | 45.82% | -- | -113.28% |
| SG&A Expenses | -27.91% | -0.26% | 15.77% | 47.02% | 106.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.18% | -24.72% | -11.80% | -34.57% | 109.31% |
| Operating Income | 37.59% | 24.32% | 19.50% | 34.57% | -109.31% |
| Income Before Tax | -232.69% | -360.88% | -145.38% | 59.44% | 255.46% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | -232.69% | -333.56% | -145.38% | 59.44% | 255.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -232.69% | -333.56% | -145.38% | 59.44% | 255.46% |
| EBIT | 37.59% | 24.32% | 19.50% | 34.57% | -109.31% |
| EBITDA | 37.65% | 24.35% | 19.53% | 34.63% | -109.60% |
| EPS Basic | -153.41% | -217.42% | -128.52% | 81.25% | 183.48% |
| Normalized Basic EPS | -135.16% | -217.70% | -130.41% | 61.89% | 198.49% |
| EPS Diluted | -153.41% | -218.01% | 37.85% | 81.25% | 183.38% |
| Normalized Diluted EPS | -135.16% | -217.70% | -133.36% | 61.89% | 198.49% |
| Average Basic Shares Outstanding | 148.43% | 98.90% | 59.11% | 116.35% | 86.23% |
| Average Diluted Shares Outstanding | 148.43% | 98.90% | 45.06% | 116.35% | 86.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |